Biomarker Expression in Malignant Ascites from High-Grade Serous Carcinoma Patients

A cohort of 37 malignant ascites samples from 33 high-grade serous carcinoma patients was analyzed for expression of ALDH1A1, SOX2, CD44v6, and P-glycoprotein. The data, published on figshare in April 2026, tracks biomarker profiles before and after chemotherapy to investigate adaptive resistance mechanisms.

Use Cases

• Analyze chemotherapy-induced biomarker expression changes based on pre- and post-treatment sample comparisons
• Investigate associations between specific markers like P-glycoprotein and clinical resistance based on the description
• Model biomarker profile positivity (≥1 marker >10% expression) as a potential monitoring signal
• Explore correlations between biomarker expression and patient survival outcomes mentioned in the study

Strengths

• Data from 37 samples processed via full-volume centrifugation (1–4 L) to maximize tumor cell recovery
• Includes stratified analysis by clinical response groups (e.g., platinum-sensitive patients)
• Statistical significance reported for key findings (e.g., p = 0.003 for post-chemotherapy increase)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Dataset is very small (33.9 KB), indicating limited scope

Provenance

Source

figshare admin karger

Collection Method

Immunocytochemical analysis of malignant ascites samples from a patient cohort.

Time Range

Study period not specified; data reflects samples collected before and after chemotherapy.

Freshness

Last updated 2026-04-15 09:55:35; freshness should be verified

Geography

Spatial coverage is unknown.